Atherosclerosis: Immune Cell Migration & Plaque Formation
- Researchers at LMU have pinpointed a key signaling pathway involved in the accumulation of CD8+ T cells within atherosclerotic plaques, potentially opening new avenues for treating cardiovascular disease.
- The study, led by Johan Duchêne and Remco Megens from the Institute for Cardiovascular Prevention (IPEK), sheds light on how these immune cells are recruited to plaques.
- Laura Parma, the study's first author, emphasized the importance of understanding the recruitment process to better define the role of CD8+ T cells.
researchers have uncovered a critical link between immune cell migration and plaque formation in atherosclerosis. This groundbreaking study reveals how the CXCL12-CXCR4 signaling pathway drives the accumulation of CD8+ T cells within artery plaques, illuminating a key mechanism in cardiovascular disease.The research highlights that chronic inflammation in blood vessel walls, driven by CD8+ T cell recruitment, is significantly influenced by this pathway. Blocking this signaling process reduces T cell migration, offering potential for innovative therapeutic strategies. The findings, lead by researchers at LMU, build on the understanding of atherosclerosis, initially attributing plaque formation primarily to macrophages. Discover how targeting the CXCL12-CXCR4 pathway, as indicated by News Directory 3, could lead to new treatments for heart disease. Explore what’s next in the development of targeted therapies to slow the progression of atherosclerosis.
CD8+ T Cells’ Role in Atherosclerosis Unveiled
Updated June 7, 2025
Researchers at LMU have pinpointed a key signaling pathway involved in the accumulation of CD8+ T cells within atherosclerotic plaques, potentially opening new avenues for treating cardiovascular disease. Atherosclerosis, characterized by chronic inflammation of blood vessel walls, is a leading cause of life-threatening conditions.
The study, led by Johan Duchêne and Remco Megens from the Institute for Cardiovascular Prevention (IPEK), sheds light on how these immune cells are recruited to plaques. While macrophages and foam cells were initially considered primary drivers of plaque formation, recent research highlights the significant presence of CD8+ T cells in human atherosclerotic plaques.
Laura Parma, the study’s first author, emphasized the importance of understanding the recruitment process to better define the role of CD8+ T cells. using a 3D tissue culture model, the scientists observed that CD8+ T cells congregated near newly formed blood vessels within the plaques. Further analysis revealed high levels of the signaling protein CXCL12 expressed by the endothelial cells of these vessels.
The team then investigated the role of CXCL12 in CD8+ cell recruitment by blocking its receptor, CXCR4, on the T cells. Duchêne stated that blocking the CXCL12-CXCR4 signaling pathway significantly reduced CD8+ T cell migration into atherosclerosis plaques, indicating its crucial role in the process.
“This did indeed lead to a significant reduction in CD8+ T cell migration into atherosclerosis plaques,” affirms Duchêne,”suggesting that the CXCL12-CXCR4 signaling pathway plays a key role in this process.”
Megens concluded that these findings offer new therapeutic approaches by influencing immune cell infiltration in atherosclerotic plaques,potentially leading to novel treatments for cardiovascular diseases.Targeting the CXCL12-CXCR4 pathway could offer a new strategy in managing atherosclerosis and related conditions.
What’s next
Future research will focus on developing targeted therapies that disrupt the CXCL12-CXCR4 signaling pathway to reduce CD8+ T cell infiltration and slow the progression of atherosclerosis. Clinical trials will be needed to assess the safety and efficacy of these new treatments.